ALSAN QUADRO
Soprema Australia Pty Ltd

Chemwatch Hazard Alert Code: **2**

Chemwatch: **5478-37**
Version No: **2.1.10.8**
Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Issue Date: **13/07/2021**
Print Date: **20/07/2021**
L.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	ALSAN QUADRO
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base) or PAINT RELATED MATERIAL (including paint thinning or reducing compound)
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Use according to manufacturer's directions.

Details of the supplier of the safety data sheet

Registered company name	**Soprema Australia Pty Ltd**
Address	Unit 2 / 109 Metrolink Circuit Campbellfield VIC 3061 Australia
Telephone	+61 3 9308 7962
Fax	Not Available
Website	Not Available
Email	orders@soprema.com.au

Emergency telephone number

Association / Organisation	**Soprema Australia Pty Ltd**
Emergency telephone numbers	042 595 2526 (Cruz Utanga: Mon-Fri 7.30am to 4pm)
Other emergency telephone numbers	Not Available

SECTION 2 Hazards identification

Classification of the substance or mixture

Poisons Schedule	S6
Classification [1]	Flammable Liquid Category 3, Skin Corrosion/Irritation Category 2, Skin Sensitizer Category 1, Eye Irritation Category 2A, Respiratory Sensitizer Category 1, Specific target organ toxicity - single exposure Category 3 (narcotic effects), Carcinogenicity Category 2, Acute Aquatic Hazard Category 3
Legend:	*1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI*

Label elements

Hazard pictogram(s)	
Signal word	**Danger**

Hazard statement(s)

H226	Flammable liquid and vapour.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H336	May cause drowsiness or dizziness.
H351	Suspected of causing cancer.
H402	Harmful to aquatic life.

Page 1 continued...

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P261	Avoid breathing mist/vapours/spray.
P271	Use only a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P284	[In case of inadequate ventilation] wear respiratory protection.
P240	Ground and bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/intrinsically safe equipment.
P242	Use non-sparking tools.
P243	Take action to prevent static discharges.
P273	Avoid release to the environment.
P264	Wash all exposed external body areas thoroughly after handling.
P272	Contaminated work clothing should not be allowed out of the workplace.

Precautionary statement(s) Response

P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P308+P313	IF exposed or concerned: Get medical advice/ attention.
P342+P311	If experiencing respiratory symptoms: Call a POISON CENTER/doctor/physician/first aider.
P370+P378	In case of fire: Use alcohol resistant foam or normal protein foam to extinguish.
P302+P352	IF ON SKIN: Wash with plenty of water and soap.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P312	Call a POISON CENTER/doctor/physician/first aider/if you feel unwell.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P337+P313	If eye irritation persists: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.
P303+P361+P353	IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water [or shower].

Precautionary statement(s) Storage

P403+P235	Store in a well-ventilated place. Keep cool.
P405	Store locked up.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
68132-86-5	25-<50	TDI, polytetrahydrofuran, propoxylated
1330-20-7	10-<25	xylene
100-41-4	2.5-<10	ethylbenzene
68512-30-1	2.5-<10	hydrocarbons, C9-unsaturated, polymers with phenol
28182-81-2	<2.5	hexamethylene diisocyanate polymer
4394-85-8	<2.5	4-formylmorpholine
19438-60-9	<2.5	4-methylhexahydrophthalic anhydride
108-88-3	<2.5	toluene
584-84-9	<2.5	toluene-2,4-diisocyanate
55406-53-6	<2.5	3-iodo-2-propynyl butyl carbamate
Legend:	*1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available*	

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: ▸ Wash out immediately with fresh running water. ▸ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. ▸ Seek medical attention without delay; if pain persists or recurs seek medical attention.

Continued...

	▸ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin or hair contact occurs: ▸ Immediately flush body and clothes with large amounts of water, using safety shower if available. ▸ Quickly remove all contaminated clothing, including footwear. ▸ Wash skin and hair with running water. Continue flushing with water until advised to stop by the Poisons Information Centre. ▸ Transport to hospital, or doctor.
Inhalation	▸ If fumes or combustion products are inhaled remove from contaminated area. ▸ Lay patient down. Keep warm and rested. ▸ Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. ▸ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. ▸ Transport to hospital, or doctor, without delay.
Ingestion	▸ If swallowed do **NOT** induce vomiting. ▸ If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. ▸ Observe the patient carefully. ▸ Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. ▸ Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. ▸ Seek medical advice. ▸ Avoid giving milk or oils. ▸ Avoid giving alcohol. ▸ If spontaneous vomiting appears imminent or occurs, hold patient's head down, lower than their hips to help avoid possible aspiration of vomitus.

Indication of any immediate medical attention and special treatment needed

Any material aspirated during vomiting may produce lung injury. Therefore emesis should not be induced mechanically or pharmacologically. Mechanical means should be used if it is considered necessary to evacuate the stomach contents; these include gastric lavage after endotracheal intubation. If spontaneous vomiting has occurred after ingestion, the patient should be monitored for difficult breathing, as adverse effects of aspiration into the lungs may be delayed up to 48 hours.
Treat symptomatically.

SECTION 5 Firefighting measures

Extinguishing media

- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog - Large fires only.

Special hazards arising from the substrate or mixture

Fire Incompatibility	▸ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Advice for firefighters

Fire Fighting	▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ May be violently or explosively reactive. ▸ Wear breathing apparatus plus protective gloves. ▸ Prevent, by any means available, spillage from entering drains or water course. ▸ If safe, switch off electrical equipment until vapour fire hazard removed. ▸ Use water delivered as a fine spray to control fire and cool adjacent area. ▸ Avoid spraying water onto liquid pools. ▸ **DO NOT** approach containers suspected to be hot. ▸ Cool fire exposed containers with water spray from a protected location. ▸ If safe to do so, remove containers from path of fire.
Fire/Explosion Hazard	▸ Liquid and vapour are flammable. ▸ Moderate fire hazard when exposed to heat or flame. ▸ Vapour forms an explosive mixture with air. ▸ Moderate explosion hazard when exposed to heat or flame. ▸ Vapour may travel a considerable distance to source of ignition. ▸ Heating may cause expansion or decomposition leading to violent rupture of containers. ▸ On combustion, may emit toxic fumes of carbon monoxide (CO). Combustion products include: carbon dioxide (CO_2) carbon monoxide (CO) isocyanates and minor amounts of hydrogen cyanide hydrogen iodide nitrogen oxides (NOx) other pyrolysis products typical of burning organic material.
HAZCHEM	•3Y

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Continued...

Minor Spills	▸ Remove all ignition sources. ▸ Clean up all spills immediately. ▸ Avoid breathing vapours and contact with skin and eyes. ▸ Control personal contact with the substance, by using protective equipment. ▸ Contain and absorb small quantities with vermiculite or other absorbent material. ▸ Wipe up. ▸ Collect residues in a flammable waste container.
Major Spills	▸ Clear area of personnel and move upwind. ▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ May be violently or explosively reactive. ▸ Wear breathing apparatus plus protective gloves. ▸ Prevent, by any means available, spillage from entering drains or water course. ▸ Consider evacuation (or protect in place). ▸ No smoking, naked lights or ignition sources. ▸ Increase ventilation. ▸ Stop leak if safe to do so. ▸ Water spray or fog may be used to disperse /absorb vapour. ▸ Contain spill with sand, earth or vermiculite. ▸ Use only spark-free shovels and explosion proof equipment. ▸ Collect recoverable product into labelled containers for recycling. ▸ Absorb remaining product with sand, earth or vermiculite. ▸ Collect solid residues and seal in labelled drums for disposal. ▸ Wash area and prevent runoff into drains. ▸ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	▸ Containers, even those that have been emptied, may contain explosive vapours. ▸ Do NOT cut, drill, grind, weld or perform similar operations on or near containers. ▸ **DO NOT** allow clothing wet with material to stay in contact with skin ▸ Electrostatic discharge may be generated during pumping - this may result in fire. ▸ Ensure electrical continuity by bonding and grounding (earthing) all equipment. ▸ Restrict line velocity during pumping in order to avoid generation of electrostatic discharge (<=1 m/sec until fill pipe submerged to twice its diameter, then <= 7 m/sec). ▸ Avoid splash filling. ▸ Do NOT use compressed air for filling discharging or handling operations. ▸ Avoid all personal contact, including inhalation. ▸ Wear protective clothing when risk of overexposure occurs. ▸ Use in a well-ventilated area. ▸ Prevent concentration in hollows and sumps. ▸ **DO NOT** enter confined spaces until atmosphere has been checked. ▸ Avoid smoking, naked lights or ignition sources. ▸ Avoid generation of static electricity. ▸ **DO NOT** use plastic buckets. ▸ Earth all lines and equipment. ▸ Use spark-free tools when handling. ▸ Avoid contact with incompatible materials. ▸ When handling, **DO NOT** eat, drink or smoke. ▸ Keep containers securely sealed when not in use. ▸ Avoid physical damage to containers. ▸ Always wash hands with soap and water after handling. ▸ Work clothes should be laundered separately. ▸ Use good occupational work practice. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS. ▸ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.
Other information	▸ Store in original containers in approved flammable liquid storage area. ▸ Store away from incompatible materials in a cool, dry, well-ventilated area. ▸ **DO NOT** store in pits, depressions, basements or areas where vapours may be trapped. ▸ No smoking, naked lights, heat or ignition sources. ▸ Storage areas should be clearly identified, well illuminated, clear of obstruction and accessible only to trained and authorised personnel - adequate security must be provided so that unauthorised personnel do not have access. ▸ Store according to applicable regulations for flammable materials for storage tanks, containers, piping, buildings, rooms, cabinets, allowable quantities and minimum storage distances. ▸ Use non-sparking ventilation systems, approved explosion proof equipment and intrinsically safe electrical systems. ▸ Have appropriate extinguishing capability in storage area (e.g. portable fire extinguishers - dry chemical, foam or carbon dioxide) and flammable gas detectors. ▸ Keep adsorbents for leaks and spills readily available. ▸ Protect containers against physical damage and check regularly for leaks. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS. In addition, for tank storages (where appropriate): ▸ Store in grounded, properly designed and approved vessels and away from incompatible materials. ▸ For bulk storages, consider use of floating roof or nitrogen blanketed vessels; where venting to atmosphere is possible, equip storage tank vents with flame arrestors; inspect tank vents during winter conditions for vapour/ ice build-up. ▸ Storage tanks should be above ground and diked to hold entire contents. for commercial quantities of isocyanates: · Isocyanates should be stored in adequately bunded areas. Nothing else should be kept within the same bunding. Pre-polymers need not be segregated. Drums of isocyanates should be stored under cover, out of direct sunlight, protected from rain, protected from physical damage and well away from moisture, acids and alkalis. · Where isocyanates are stored at elevated temperatures to prevent solidifying, adequate controls should be installed to prevent the high temperatures and precautions against fire should be taken. · Where stored in tanks, the more reactive isocyanates should be blanketed with a non-reactive gas such as nitrogen and equipped with absorptive type breather valve (to prevent vapour emissions)..

Continued...

	· Transfer systems for isocyanates in bulk storage should be fully enclosed and use pump or vacuum systems. Warning signs, in appropriate languages, should be posted where necessary. · Areas in which polyurethane foam products are stored should be supplied with good general ventilation. Residual amounts of unreacted isocyanate may be present in the finished foam, resulting in hazardous atmospheric concentrations. · Ideal storage temperature range is dependent on the specific polymer due to viscosity and melting point differences between the polymers. Use 25 deg C (77 deg F) to 30 deg C (86 deg F) as a guideline to most liquid isocyanates for optimum storage temperature. If some isocyanates are stored at or below a temperature of 25 deg C (77 deg F), crystallization and settling of the isocyanate may occur. Storage in a cold warehouse can cause crystals to form. These crystals can settle to the bottom of the container. If crystals do form, they can be melted easily with moderate heat. It is suggested that a container the size of a drum be warmed for 16-24 hours at sufficient temperature to melt the crystals. When the crystals are melted, the container should be agitated by rolling or stirring, until the contents are homogenous. Since heated isocyanate will generate vapors more rapidly than product stored at 25 deg C (77 deg F), be sure to follow the precautions under the Personal Protection.

Conditions for safe storage, including any incompatibilities

Suitable container	▸ Packing as supplied by manufacturer. ▸ Plastic containers may only be used if approved for flammable liquid. ▸ Check that containers are clearly labelled and free from leaks. ▸ For low viscosity materials (i) : Drums and jerry cans must be of the non-removable head type. (ii) : Where a can is to be used as an inner package, the can must have a screwed enclosure. ▸ For materials with a viscosity of at least 2680 cSt. (23 deg. C) ▸ For manufactured product having a viscosity of at least 250 cSt. (23 deg. C) ▸ Manufactured product that requires stirring before use and having a viscosity of at least 20 cSt (25 deg. C): (i) Removable head packaging; (ii) Cans with friction closures and (iii) low pressure tubes and cartridges may be used. ▸ Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact with inner and outer packages ▸ In addition, where inner packagings are glass and contain liquids of packing group I there must be sufficient inert absorbent to absorb any spillage, unless the outer packaging is a close fitting moulded plastic box and the substances are not incompatible with the plastic.
Storage incompatibility	For alkyl aromatics: The alkyl side chain of aromatic rings can undergo oxidation by several mechanisms. The most common and dominant one is the attack by oxidation at benzylic carbon as the intermediate formed is stabilised by resonance structure of the ring. ▸ Following reaction with oxygen and under the influence of sunlight, a hydroperoxide at the alpha-position to the aromatic ring, is the primary oxidation product formed (provided a hydrogen atom is initially available at this position) - this product is often short-lived but may be stable dependent on the nature of the aromatic substitution; a secondary C-H bond is more easily attacked than a primary C-H bond whilst a tertiary C-H bond is even more susceptible to attack by oxygen ▸ Monoalkylbenzenes may subsequently form monocarboxylic acids; alkyl naphthalenes mainly produce the corresponding naphthalene carboxylic acids. ▸ Oxidation in the presence of transition metal salts not only accelerates but also selectively decomposes the hydroperoxides. ▸ Hock-rearrangement by the influence of strong acids converts the hydroperoxides to hemiacetals. Peresters formed from the hydroperoxides undergo Criegee rearrangement easily. ▸ Alkali metals accelerate the oxidation while CO2 as co-oxidant enhances the selectivity. ▸ Microwave conditions give improved yields of the oxidation products. ▸ Photo-oxidation products may occur following reaction with hydroxyl radicals and NOx - these may be components of photochemical smogs. Oxidation of Alkylaromatics: T.S.S Rao and Shubhra Awasthi: E-Journal of Chemistry Vol 4, No. 1, pp 1-13 January 2007 ▸ Vigorous reactions, sometimes amounting to explosions, can result from the contact between aromatic rings and strong oxidising agents. ▸ Aromatics can react exothermically with bases and with diazo compounds.

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	xylene	Xylene (o-, m-, p- isomers)	80 ppm / 350 mg/m3	655 mg/m3 / 150 ppm	Not Available	Not Available
Australia Exposure Standards	ethylbenzene	Ethyl benzene	100 ppm / 434 mg/m3	543 mg/m3 / 125 ppm	Not Available	Not Available
Australia Exposure Standards	hexamethylene diisocyanate polymer	Isocyanates, all (as-NCO)	0.02 mg/m3	0.07 mg/m3	Not Available	Not Available
Australia Exposure Standards	toluene	Toluene	50 ppm / 191 mg/m3	574 mg/m3 / 150 ppm	Not Available	Not Available
Australia Exposure Standards	toluene-2,4-diisocyanate	Toluene-2,4-diisocyanate (TDI)	0.02 mg/m3	0.07 mg/m3	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
xylene	Not Available	Not Available	Not Available
ethylbenzene	Not Available	Not Available	Not Available
hexamethylene diisocyanate polymer	7.8 mg/m3	86 mg/m3	510 mg/m3
toluene	Not Available	Not Available	Not Available
toluene-2,4-diisocyanate	0.02 ppm	0.083 ppm	0.51 ppm
toluene-2,4-diisocyanate	Not Available	Not Available	Not Available
3-iodo-2-propynyl butyl carbamate	3.3 mg/m3	36 mg/m3	220 mg/m3

Ingredient	Original IDLH	Revised IDLH
TDI, polytetrahydrofuran,	Not Available	Not Available

Continued...

Ingredient	Original IDLH	Revised IDLH
propoxylated		
xylene	900 ppm	Not Available
ethylbenzene	800 ppm	Not Available
hydrocarbons, C9-unsaturated, polymers with phenol	Not Available	Not Available
hexamethylene diisocyanate polymer	Not Available	Not Available
4-formylmorpholine	Not Available	Not Available
4-methylhexahydrophthalic anhydride	Not Available	Not Available
toluene	500 ppm	Not Available
toluene-2,4-diisocyanate	2.5 ppm	Not Available
3-iodo-2-propynyl butyl carbamate	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
TDI, polytetrahydrofuran, propoxylated	D	> 0.1 to ≤ 1 ppm
hydrocarbons, C9-unsaturated, polymers with phenol	E	≤ 0.1 ppm
4-formylmorpholine	E	≤ 0.1 ppm
4-methylhexahydrophthalic anhydride	E	≤ 0.1 ppm
3-iodo-2-propynyl butyl carbamate	E	≤ 0.01 mg/m³
Notes:	*Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.*	

MATERIAL DATA

Exposure controls

Appropriate engineering controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.
The basic types of engineering controls are:
Process controls which involve changing the way a job activity or process is done to reduce the risk.
Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.
Employers may need to use multiple types of controls to prevent employee overexposure.

For flammable liquids and flammable gases, local exhaust ventilation or a process enclosure ventilation system may be required. Ventilation equipment should be explosion-resistant.
Spraying of material or material in admixture with other components must be carried out in conditions conforming to local state regulations. Local exhaust ventilation with full face air supplied breathing apparatus (hood or helmet type) is normally required. Unprotected personnel must vacate spraying area.
NOTE: Isocyanate vapours will not be adequately absorbed by organic vapour respirators. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 4-10 m/s (800-2000 f/min.) for extraction of solvents generated by spraying at a point 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Personal protection



Eye and face protection

- Safety glasses with side shields.
- Chemical goggles.
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing

Continued...

	the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]
Skin protection	See Hand protection below
Hands/feet protection	**NOTE:** ▸ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact. ▸ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed. The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application. The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice. Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended. Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: · frequency and duration of contact, · chemical resistance of glove material, · glove thickness and · dexterity Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent). · When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. · When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. · Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use. · Contaminated gloves should be replaced. As defined in ASTM F-739-96 in any application, gloves are rated as: · Excellent when breakthrough time > 480 min · Good when breakthrough time > 20 min · Fair when breakthrough time < 20 min · Poor when glove material degrades For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended. It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times. Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers' technical data should always be taken into account to ensure selection of the most appropriate glove for the task. Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example: · Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of. · Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended. ▸ Do NOT wear natural rubber (latex gloves). ▸ Isocyanate resistant materials include Teflon, Viton, nitrile rubber and some PVA gloves. ▸ Protective gloves and overalls should be worn as specified in the appropriate national standard. ▸ Contaminated garments should be removed promptly and should not be re-used until they have been decontaminated. ▸ NOTE: Natural rubber, neoprene, PVC can be affected by isocyanates ▸ **DO NOT** use skin cream unless necessary and then use only minimum amount. ▸ Isocyanate vapour may be absorbed into skin cream and this increases hazard.
Body protection	See Other protection below
Other protection	All employees working with isocyanates must be informed of the hazards from exposure to the contaminant and the precautions necessary to prevent damage to their health. They should be made aware of the need to carry out their work so that as little contamination as possible is produced, and of the importance of the proper use of all safeguards against exposure to themselves and their fellow workers. Adequate training, both in the proper execution of the task and in the use of all associated engineering controls, as well as of any personal protective equipment, is essential. Employees exposed to contamination hazards should be educated in the need for, and proper use of, facilities, clothing and equipment and thereby maintain a high standard of personal cleanliness. Special attention should be given to ensuring that all personnel understand instructions, especially newly recruited employees and those with local-language difficulties, where they are known. ▸ Overalls. ▸ PVC Apron. ▸ PVC protective suit may be required if exposure severe. ▸ Eyewash unit. ▸ Ensure there is ready access to a safety shower. ▸ Some plastic personal protective equipment (PPE) (e.g. gloves, aprons, overshoes) are not recommended as they may produce static electricity. ▸ For large scale or continuous use wear tight-weave non-static clothing (no metallic fasteners, cuffs or pockets). ▸ Non sparking safety or conductive footwear should be considered. Conductive footwear describes a boot or shoe with a sole made from a conductive compound chemically bound to the bottom components, for permanent control to electrically ground the foot an shall dissipate static electricity from the body to reduce the possibility of ignition of volatile compounds. Electrical resistance must range between 0 to 500,000 ohms. Conductive shoes should be stored in lockers close to the room in which they are worn. Personnel who have been issued conductive footwear should not wear them from their place of work to their homes and return.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:
"Forsberg Clothing Performance Index".
The effect(s) of the following substance(s) are taken into account in the ***computer-generated*** selection:

Respiratory protection

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of

Continued...

ALSAN QUADRO

Material	CPI
VITON	A
TEFLON	B
BUTYL	C
BUTYL/NEOPRENE	C
CPE	C
HYPALON	C
NAT+NEOPR+NITRILE	C
NATURAL+NEOPRENE	C
NEOPRENE	C
NEOPRENE/NATURAL	C
NITRILE	C
NITRILE+PVC	C
PE/EVAL/PE	C
PVA	C
PVC	C
PVDC/PE/PVDC	C
SARANEX-23	C
SARANEX-23 2-PLY	C
VITON/CHLOROBUTYL	C
VITON/NEOPRENE	C

* CPI - Chemwatch Performance Index
A: Best Selection
B: Satisfactory; may degrade after 4 hours continuous immersion
C: Poor to Dangerous Choice for other than short term immersion
NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -
* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS P2	-	A-PAPR-AUS / Class 1 P2
up to 50 x ES	-	A-AUS / Class 1 P2	-
up to 100 x ES	-	A-2 P2	A-PAPR-2 P2 ^

^ - Full-face
A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

For spraying or operations which might generate aerosols:
Full face respirator with supplied air.

- In certain circumstances, personal protection of the individual employee is necessary. Personal protective devices should be regarded as being supplementary to substitution and engineering control and should not be used in preference to them as they do nothing to eliminate the hazard.
- However, in some situations, minimising exposure to isocyanates by enclosure and ventilation is not possible, and occupational exposure standards may be exceeded, particularly during on-site mixing of paints, spray-painting, foaming and maintenance of machine and ventilation systems. In these situations, air-line respirators or self-contained breathing apparatus complying with the appropriate nationals standard must be used.
- Organic vapour respirators with particulate pre- filters and powered, air-purifying respirators are NOT suitable.
- Personal protective equipment must be appropriately selected, individually fitted and workers trained in their correct use and maintenance. Personal protective equipment must be regularly checked and maintained to ensure that the worker is being protected.
- Air- line respirators or self-contained breathing apparatus complying with the appropriate national standard should be used during the clean-up of spills and the repair or clean-up of contaminated equipment and similar situations which cause emergency exposures to hazardous atmospheric concentrations of isocyanate.

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Viscous flammable liquid; not miscible with water.

Physical state	Liquid	**Relative density (Water = 1)**	1.14
Odour	Not Available	**Partition coefficient n-octanol / water**	Not Available
Odour threshold	Not Available	**Auto-ignition temperature (°C)**	Not Available
pH (as supplied)	Not Applicable	**Decomposition temperature**	Not Available
Melting point / freezing point (°C)	Not Available	**Viscosity (cSt)**	10000
Initial boiling point and boiling range (°C)	Not Available	**Molecular weight (g/mol)**	Not Applicable
Flash point (°C)	34	**Taste**	Not Available
Evaporation rate	Not Available	**Explosive properties**	Not Available
Flammability	Flammable.	**Oxidising properties**	Not Available
Upper Explosive Limit (%)	Not Available	**Surface Tension (dyn/cm or mN/m)**	Not Available
Lower Explosive Limit (%)	Not Available	**Volatile Component (%vol)**	Not Available
Vapour pressure (kPa)	110	**Gas group**	Not Available
Solubility in water	Immiscible	**pH as a solution (%)**	Not Available
Vapour density (Air = 1)	Not Available	**VOC g/L**	245

SECTION 10 Stability and reactivity

Continued...

Reactivity	See section 7
Chemical stability	▸ Unstable in the presence of incompatible materials. ▸ Product is considered stable. ▸ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo. Limited evidence or practical experience suggests that the material may produce irritation of the respiratory system, in a significant number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Inhalation hazard is increased at higher temperatures. Central nervous system (CNS) depression may include nonspecific discomfort, symptoms of giddiness, headache, dizziness, nausea, anaesthetic effects, slowed reaction time, slurred speech and may progress to unconsciousness. Serious poisonings may result in respiratory depression and may be fatal. Acute effects from inhalation of high concentrations of vapour are pulmonary irritation, including coughing, with nausea; central nervous system depression - characterised by headache and dizziness, increased reaction time, fatigue and loss of co-ordination
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual.
Skin Contact	The material produces moderate skin irritation; evidence exists, or practical experience predicts, that the material either ▸ produces moderate inflammation of the skin in a substantial number of individuals following direct contact, and/or ▸ produces significant, but moderate, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
Eye	Evidence exists, or practical experience predicts, that the material may cause severe eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Eye contact may cause significant inflammation with pain. Corneal injury may occur; permanent impairment of vision may result unless treatment is prompt and adequate. Repeated or prolonged exposure to irritants may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.
Chronic	On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment. Practical evidence shows that inhalation of the material is capable of inducing a sensitisation reaction in a substantial number of individuals at a greater frequency than would be expected from the response of a normal population. Pulmonary sensitisation, resulting in hyperactive airway dysfunction and pulmonary allergy may be accompanied by fatigue, malaise and aching. Significant symptoms of exposure may persist for extended periods, even after exposure ceases. Symptoms can be activated by a variety of nonspecific environmental stimuli such as automobile exhaust, perfumes and passive smoking. Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals. Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive. Substances than can cuase occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers Wherever it is reasonably practicable, exposure to substances that can cuase occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive. Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance. Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests. Persons with a history of asthma or other respiratory problems or are known to be sensitised, should not be engaged in any work involving the handling of isocyanates. The chemistry of reaction of isocyanates, as evidenced by MDI, in biological milieu is such that in the event of a true exposure of small MDI doses to the mouth, reactions will commence at once with biological macromolecules in the buccal region and will continue along the digestive tract prior to reaching the stomach. Reaction products will be a variety of polyureas and macromolecular conjugates with for example mucus, proteins and cell components. This is corroborated by the results from an MDI inhalation study. Following an inhalation exposure of rats to radiolabelled MDI, 79% of the dose was excreted in faeces. The faecal excretion in these animals was considered entirely due to ingestion of radioactivity from grooming and ingestion of deposited material from the nasopharangeal region via the mucociliary escalator, i.e. not following systemic absorption. The faecal radioactivity was tentatively identified as mixed molecular weight polyureas derived from MDI. Diamine was not present. Thus, for MDI and diisocyanates in general the oral gavage dosing route is inappropriate for toxicological studies and risk assessment. It is expected that oral gavage dosing will result in a similar outcome to that produced by TDI or MDI, that is (1) reaction with stomach contents

Continued...

and (2) polymerization to solid polyureas.

- Reaction with stomach contents is very plausibly described in case reports of accidental ingestion of polymeric MDI based glue in domestic animals. Extensive polymerization and CO2 liberation resulting in an expansion of the gastric content is described in the stomach, without apparent acute chemical toxicity
- Polyurea formation in organic and aqueous phases has been described. In this generally accepted chemistry of hydrolysis of an isocyanate the initially produced carbamate decarboxylates to an amine which. The amine, as a reactive intermediate, then reacts very readily with the present isocyanate to produce a solid and inert polyurea. This urea formation acts as a pH buffer in the stomach, thus promoting transformation of the diisocyanate into polyurea, even under the acidic conditions.

At the resorbtive tissues in the small intestine, these high molecular reaction products are likely to be of very low bioavailability, which is substantiated by the absence of systemic toxicity in acute oral bioassays with rats at the OECD limit dose (LC50>2 g/kg bw).
The respiratory tract may be regarded as the main entry for systemically available isocyanates as evidenced following MDI.exposures.
A detailed summary on urinary, plasma and in vitro metabolite studies is provided below. Taken together, all available studies provide convincing evidence that MDI-protein adduct and MDI-metabolite formation proceeds:

- via formation of a labile isocyanate glutathione (GSH)-adduct,
- then transfer to a more stable adduct with larger proteins, and
- without formation of free MDA. MDA reported as a metabolite is actually formed by analytical workup procedures (strong acid or base hydrolysis) and is not an identified metabolite in urine or blood

A 90-day inhalation study in rats with polymeric MDI (6 hours/day, 5 days/week) produced moderate to severe hyperplastic inflammatory lesions in the nasal cavities and lungs at levels of 8 mg/m3 or greater.
Rats exposed for two years to a respirable aerosol of polymeric MDI exhibited chronic pulmonary irritation at high concentrations. Only at the highest level (6 mg/m3),was there a significant incidence of a benign tumour of the lung (adenoma) and one malignant tumour (adenocarcinoma).There were no lung tumours at 1 mg/m3 and no effects at 0.2 mg/m3. Overall, the tumour incidence, both benign and malignant and the number of animals with the tumours were not different from controls.The increased incidence of lung tumours is associated with prolonged respiratory irritation and the concurrent accumulation of yellow material in the lung, which occurred throughout the study.In the absence of prolonged exposure to high concentrations leading to chronic irritation and lung damage,it is highly unlikely that tumour formation will occur.
Industrial workers exposed to a maximum level of ethylbenzene of 0.06 mg/l (14 ppm) reported headaches and irritability and tired quickly. Functional nervous system disturbances were found in some workers employed for over 7 years whilst other workers had enlarged livers.
Prolonged and repeated exposure may be harmful to the central nervous system (CNS), upper respiratory tract, and/ or may cause liver disorders. It may also cause drying, scaling and blistering of the skin.
Rats and mice exposed to ethylbenzene for 6 hours daily, 5 days a week for 104 and 103 weeks respectively showed a statistically significant increase in kidney tumours in male and female rats, lung tumours in male mice, and liver tumours in female mice exposed to 750 ppm ethylbenzene.
Prolonged or repeated contact with xylenes may cause defatting dermatitis with drying and cracking. Chronic inhalation of xylenes has been associated with central nervous system effects, loss of appetite, nausea, ringing in the ears, irritability, thirst anaemia, mucosal bleeding, enlarged liver and hyperplasia. Exposure may produce kidney and liver damage. In chronic occupational exposure, xylene (usually mix ed with other solvents) has produced irreversible damage to the central nervous system and ototoxicity (damages hearing and increases sensitivity to noise), probably due to neurotoxic mechanisms.
Industrial workers exposed to xylene with a maximum level of ethyl benzene of 0.06 mg/l (14 ppm) reported headaches and irritability and tired quickly. Functional nervous system disturbances were found in some workers employed for over 7 years whilst other workers had enlarged livers.
Xylene has been classed as a developmental toxin in some jurisdictions.
Small excess risks of spontaneous abortion and congenital malformation were reported amongst women exposed to xylene in the first trimester of pregnancy. In all cases, however, the women were also been exposed to other substances. Evaluation of workers chronically exposed to xylene has demonstrated lack of genotoxicity. Exposure to xylene has been associated with increased risks of haemopoietic malignancies but, again, simultaneous exposure to other substances (including benzene) complicates the picture. A long-term gavage study to mixed xylenes (containing 17% ethyl benzene) found no evidence of carcinogenic activity in rats and mice of either sex.

Harmful: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed.
Isocyanate vapours/mists are irritating to the upper respiratory tract and lungs; the response may be severe enough to produce bronchitis with wheezing, gasping and severe distress, even sudden loss of consciousness, and pulmonary oedema. Possible neurological symptoms arising from isocyanate exposure include headache, insomnia, euphoria, ataxia, anxiety neurosis, depression and paranoia. Gastrointestinal disturbances are characterised by nausea and vomiting. Pulmonary sensitisation may produce asthmatic reactions ranging from minor breathing difficulties to severe allergic attacks; this may occur following a single acute exposure or may develop without warning after a period of tolerance. A respiratory response may occur following minor skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities.
Isocyanate-containing vapours/ mists may cause inflammation of eyes and nasal passages.
Onset of symptoms may be immediate or delayed for several hours after exposure. Sensitised people can react to very low levels of airborne isocyanates. Unprotected or sensitised persons should not be allowed to work in situations allowing exposure to this material.

ALSAN QUADRO

TOXICITY	IRRITATION
Not Available	Not Available

TDI, polytetrahydrofuran, propoxylated

TOXICITY	IRRITATION
Not Available	Not Available

xylene

TOXICITY	IRRITATION
Dermal (rabbit) LD50: >1700 mg/kg[2]	Eye (human): 200 ppm irritant
Inhalation(Rat) LC50; 5922 ppm4h[1]	Eye (rabbit): 5 mg/24h SEVERE
Oral(Mouse) LD50; 2119 mg/kg[2]	Eye (rabbit): 87 mg mild
	Eye: adverse effect observed (irritating)[1]
	Skin (rabbit):500 mg/24h moderate
	Skin: adverse effect observed (irritating)[1]

ethylbenzene

TOXICITY	IRRITATION
Dermal (rabbit) LD50: >5000 mg/kg[2]	Eye (rabbit): 500 mg - SEVERE
Inhalation(Rat) LC50; 17.2 mg/l4h[2]	Eye: no adverse effect observed (not irritating)[1]
Oral(Rat) LD50; ~3523 mg/kg[2]	Skin (rabbit): 15 mg/24h mild

Continued...

		Skin: no adverse effect observed (not irritating)[1]

hydrocarbons, C9-unsaturated, polymers with phenol	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >10500 mg/kg[2]	Not Available
	Oral(Rat) LD50; 1200 mg/kg[2]	

hexamethylene diisocyanate polymer	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >2000 mg/kg[1]	Skin (rabbit): 500 mg - moderate
	Inhalation(Rat) LC50; 0.052-0.5 mg/L4h[1]	
	Oral(Rat) LD50; >2000 mg/kg[1]	

4-formylmorpholine	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >16000 mg/kg[2]	Eye (rabbit): 500 mg/24h - mild
	Inhalation(Rat) LC50; >=5.319 mg/l4h[1]	Eye: no adverse effect observed (not irritating)[1]
	Oral(Rat) LD50; 6500 mg/kg[2]	Skin (rabbit): 500 mg/24h - mild
		Skin: no adverse effect observed (not irritating)[1]

4-methylhexahydrophthalic anhydride	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >2000 mg/kg[1]	Eye: adverse effect observed (irritating)[1]
	Oral(Rat) LD50; >2000 mg/kg[1]	Skin: no adverse effect observed (not irritating)[1]

toluene	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >5000 mg/kg[1]	Eye (rabbit): 2mg/24h - SEVERE
	Inhalation(Rat) LC50; 12.5-28.8 mg/l4h[2]	Eye (rabbit):0.87 mg - mild
	Oral(Rat) LD50; 636 mg/kg[2]	Eye (rabbit):100 mg/30sec - mild
		Eye: adverse effect observed (irritating)[1]
		Skin (rabbit):20 mg/24h-moderate
		Skin (rabbit):500 mg - moderate
		Skin: adverse effect observed (irritating)[1]
		Skin: no adverse effect observed (not irritating)[1]

toluene-2,4-diisocyanate	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >2000 mg/kg[1]	Eye (rabbit): 100 mg - SEVERE
	Inhalation(Mouse) LC50; 10 ppm4h[2]	Eye: adverse effect observed (irritating)[1]
	Oral(Rat) LD50; >2000 mg/kg[1]	Skin (rabbit): 500 mg(open)-SEVERE
		Skin (rabbit):500 mg/24hr-moderate
		Skin: adverse effect observed (irritating)[1]

3-iodo-2-propynyl butyl carbamate	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >2000 mg/kg[1]	Eye: adverse effect observed (irreversible damage)[1]
	Inhalation(Rat) LC50; 0.63 mg/l4h[1]	Eye: Irritating
	Oral(Rat) LD50; 1056 mg/kg[1]	Skin: no adverse effect observed (not irritating)[1]
		Skin: Slight irritant

Legend:	*1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances*

TDI, POLYTETRAHYDROFURAN, PROPOXYLATED	Polyethers, for example, ethoxylated surfactants and polyethylene glycols, are highly susceptible towards air oxidation as the ether oxygens will stabilize intermediary radicals involved. Investigations of a chemically well-defined alcohol (pentaethylene glycol mono-n-dodecyl ether) ethoxylate, showed that polyethers form complex mixtures of oxidation products when exposed to air. Sensitization studies in guinea pigs revealed that the pure nonoxidized surfactant itself is nonsensitizing but that many of the investigated oxidation products are sensitizers. Two hydroperoxides were identified in the oxidation mixture, but only one (16-hydroperoxy-3,6,9,12,15-pentaoxaheptacosan-1-ol) was stable enough to be isolated. It was found to be a strong sensitizer in LLNA (local lymph node assay for detection of sensitization capacity). The formation of other hydroperoxides was indicated by the detection of their corresponding aldehydes in the oxidation mixture . On the basis of the lower irritancy, nonionic surfactants are often preferred to ionic surfactants in topical products. However, their susceptibility towards autoxidation also increases the irritation. Because of their irritating effect, it is difficult to diagnose ACD to these compounds by patch testing. Allergic Contact Dermatitis—Formation, Structural Requirements,and Reactivity of Skin Sensitizers. Ann-Therese Karlberg et al; Chem. Res. Toxicol.2008,21,53-69 Polyethylene glycols (PEGs) have a wide variety of PEG-derived mixtures due to their readily linkable terminal primary hydroxyl groups in combination with many possible compounds and complexes such as ethers, fatty acids, castor oils, amines, propylene glycols, among other derivatives. PEGs and their derivatives are broadly utilized in cosmetic products as surfactants, emulsifiers, cleansing agents, humectants, and skin conditioners. PEGs and PEG derivatives were generally regulated as safe for use in cosmetics, with the conditions that impurities and by-products, such

Continued...

	as ethylene oxides and 1,4-dioxane, which are known carcinogenic materials, should be removed before they are mixed in cosmetic formulations. Most PEGs are commonly available commercially as mixtures of different oligomer sizes in broadly- or narrowly-defined molecular weight (MW) ranges. For instance, PEG-10,000 typically designates a mixture of PEG molecules (n = 195 to 265) having an average MW of 10,000. PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE), with the three names being chemical synonyms. However, PEGs mainly refer to oligomers and polymers with molecular masses below 20,000 g/mol, while PEOs are polymers with molecular masses above 20,000 g/mol, and POEs are polymers of any molecular mass. Relatively small molecular weight PEGs are produced by the chemical reaction between ethylene oxide and water or ethylene glycol (or other ethylene glycol oligomers), as catalyzed by acidic or basic catalysts. To produce PEO or high-molecular weight PEGs, synthesis is performed by suspension polymerization. It is necessary to hold the growing polymer chain in solution during the course of the poly-condensation process. The reaction is catalyzed by magnesium-, aluminum-, or calcium-organoelement compounds. To prevent coagulation of polymer chains in the solution, chelating additives such as dimethylglyoxime are used Safety Evaluation of Polyethyene Glycol (PEG) Compounds for Cosmetic Use: Toxicol Res 2015; 31:105-136 The Korean Society of Toxicology http://doi.org/10.5487/TR.2015.31.2.105
XYLENE	Reproductive effector in rats The substance is classified by IARC as Group 3: **NOT** classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.
ETHYLBENZENE	Liver changes, utheral tract, effects on fertility, foetotoxicity, specific developmental abnormalities (musculoskeletal system) recorded. Ethylbenzene is readily absorbed following inhalation, oral, and dermal exposures, distributed throughout the body, and excreted primarily through urine. There are two different metabolic pathways for ethylbenzene with the primary pathway being the alpha-oxidation of ethylbenzene to 1-phenylethanol, mostly as the R-enantiomer. The pattern of urinary metabolite excretion varies with different mammalian species. In humans, ethylbenzene is excreted in the urine as mandelic acid and phenylgloxylic acids; whereas rats and rabbits excrete hippuric acid and phenaceturic acid as the main metabolites. Ethylbenzene can induce liver enzymes and hence its own metabolism as well as the metabolism of other substances. Ethylbenzene has a low order of acute toxicity by the oral, dermal or inhalation routes of exposure. Studies in rabbits indicate that ethylbenzene is irritating to the skin and eyes. There are numerous repeat dose studies available in a variety of species, these include: rats, mice, rabbits, guinea pig and rhesus monkeys. Hearing loss has been reported in rats (but not guinea pigs) exposed to relatively high exposures *(400 ppm and greater)* of ethylbenzene In chronic toxicity/carcinogenicity studies, both rats and mice were exposed via inhalation to 0, 75, 250 or 750 ppm for 104 weeks. In rats, the kidney was the target organ of toxicity, with renal tubular hyperplasia noted in both males and females at the 750 ppm level only. In mice, the liver and lung were the principal target organs of toxicity. In male mice at 750 ppm, lung toxicity was described as alveolar epithelial metaplasia, and liver toxicity was described as hepatocellular syncitial alteration, hypertrophy and mild necrosis; this was accompanied by increased follicular cell hyperplasia in the thyroid. As a result the NOAEL in male mice was determined to be 250 ppm. In female mice, the 750 ppm dose group had an increased incidence of eosinophilic foci in the liver (44% vs 10% in the controls) and an increased incidence in follicular cell hyperplasia in the thyroid gland. In studies conducted by the U.S. National Toxicology Program, inhalation of ethylbenzene at 750 ppm resulted in increased lung tumors in male mice, liver tumors in female mice, and increased kidney tumors in male and female rats. No increase in tumors was reported at 75 or 250 ppm. Ethylbenzene is considered to be an animal carcinogen, however, the relevance of these findings to humans is currently unknown. Although no reproductive toxicity studies have been conducted on ethylbenzene, repeated-dose studies indicate that the reproductive organs are not a target for ethylbenzene toxicity Ethylbenzene was negative in bacterial gene mutation tests and in a yeast assay on mitotic recombination. **NOTE:** Substance has been shown to be mutagenic in at least one assay, or belongs to a family of chemicals producing damage or change to cellular DNA.
HEXAMETHYLENE DIISOCYANATE POLYMER	* Bayer SDS ** Ardex SDS The material may produce moderate eye irritation leading to inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.
4-FORMYLMORPHOLINE	The material may be irritating to the eye, with prolonged contact causing inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.
4-METHYLHEXAHYDROPHTHALIC ANHYDRIDE	for cyclic anhydrides: Low molecular weight carboxylic acid anhydrides are recognized to have similar toxicological properties. Of the more extensively studied anhydrides, phthalic anhydride is most structurally similar to the cyclic anhydrides Toxicological analogy will be made to phthalic anhydride. **Acute toxicity:** Available data indicates that the cyclic anhydrides have a low acute toxicity, are respiratory and skin sensitisers and can cause corrosive eye damage. Since these compounds are considered to be sensitisers at low concentrations, exposures in the workplace are controlled to lowest possible levels. Oral LD50s for cyclic anhydrides in rats are relatively high, ranging from 958 to 4460 mg/kg. Dermal toxicity is also relatively low as indicated by dermal LD50s of > 2000 mglkg in rabbits for hexahydrophthalic anhydride (HHPA), methyltetrahydrophthalic anhydride.(MTHPA), and Nadic methyl anhydride (NMA). These values suggest a low order of acute oral and dermal toxicity. The four-hour inhalation LC50 for HHPA in rats is cited as > 1100 mg/m3 (aerosol). In a limited inhalation study on NMA, a concentration of 750 mg/m3 for 4 hours was lethal to 8 of 10 rats. As demonstrated by animal testing and human experience, anhydrides within the group can cause mild to moderate skin irritation and moderate to severe eye irritation with possible corrosive effects. For European labeling purposes (Directive 67/548/EEC, Annex I) risk (R) phrases for HHPA, methylhexahydrophthalic anhydride (MHHPA), MTHPA, and tetrahydrophthalic anhydride (THPA) are: "Risk of serious damage to the eyes. May cause sensitisation by inhalation and skin contact"" Studies in rabbits indicate that NMA also causes severe eye irritation with the possibility of permanent damage. HHPA, MTHPA, THPA, and NMA all have caused mild skin irritation in rabbits. In one test, NMA was found to be moderately irritating and no studies were found indicating potential irritant effects MHHPA may have on the skin. **Repeated dose toxicity:** MTHPA, has been tested by oral gavage using OECD Method No. 422. Rats were dosed subchronically at 0, 30, 100 and 300 mg/kg/day. On terminal sacrifice, both male and female rats dosed at 300 mglkg exhibited evidence of irritation at the site of administration, the forestomach. Less severe indications of irritation were evident in male rats at 100 mg/kg. No irritation was evident in males dosed at 30 mglkglday or females dosed at 30 mglkglday or 100 mglkglday. Aside from transient salivation in the animals dosed at 300 mg/kg/day, no adverse effects on body weight, food consumption, or other clinical signs were apparent. At termination, blood chemistry determinations indicated decreased total cholesterol and BUN as well as increased triglyceride level and adrenal weight in males. Aside from irritation at the site of administration, no specific target organ for MTHPA was elucidated. The NOELs were reported to be 30 mg/kg/day for males and 100 mg/kg/day for females. **Sensitisation:** Specific serum IgE and IgG antibodies to a fairly large number of anhydrides have been found in exposed workers. Documentation for sensitization was available for all anhydrides within the group with the exception of NMA. Based on analogy to other acid anhydrides and verbal industrial reports, NMA is expected to produce sensitisation. Allergic response to cyclic anhydrides is triggered by the ability of cyclic anhydrides to bind covalently to free amino groups; in particular, to the amino group of lysine. An immunologic hapten-protein conjugate is formed which stimulates specific immunological responses. PA and cyclic anhydrides have been associated with occupational asthma. Similarity in mechanism for allergic response to cyclic anhydrides within this group is also demonstrated by cross-sensitisation potential. Workers sensitised to MTHPA, HHPA or HHPAIMHHPA have shown marked cross-reactivity to MTHPA-human serum albumin (HAS), HHPA-HAS, and MHHPA-HAS as demonstrated by radioallergosorbent test (RAST), RAST inhibition and skin prick tests. Ring structure, methyl group substituents and position of double bonds may all affect sensitising potential of cyclic anhydrides; however differences are

Continued...

	quantitative rather than qualitative. **Reproductive/Developmental Toxicity:** A combined screening study (OECD Method No. 422) was conducted to assess repeated dose toxicity, reproductive performance and developmental toxicity potential on MTHPA. Results from this study indicates that at doses less than or equal to 300 mg/kg/day, MTHPA had no adverse effects on reproductive performance in either male or female rats and no indications of developmental toxicity were evident. Limited studies on other carboxylic acid anhydrides (i.e.: phthalic anhydride) raise the question of possible reproductive toxicity concerns.
TOLUENE	For toluene: **Acute Toxicity** Humans exposed to intermediate to high levels of toluene for short periods of time experience adverse central nervous system effects ranging from headaches to intoxication, convulsions, narcosis, and death. Similar effects are observed in short-term animal studies. **Humans -** Toluene ingestion or inhalation can result in severe central nervous system depression, and in large doses, can act as a narcotic. The ingestion of about 60 mL resulted in fatal nervous system depression within 30 minutes in one reported case. Constriction and necrosis of myocardial fibers, markedly swollen liver, congestion and haemorrhage of the lungs and acute tubular necrosis were found on autopsy. Central nervous system effects (headaches, dizziness, intoxication) and eye irritation occurred following inhalation exposure to 100 ppm toluene 6 hours/day for 4 days. Exposure to 600 ppm for 8 hours resulted in the same and more serious symptoms including euphoria, dilated pupils, convulsions, and nausea . Exposure to 10,000-30,000 ppm has been reported to cause narcosis and death Toluene can also strip the skin of lipids causing dermatitis **Animals -** The initial effects are instability and incoordination, lachrymation and sniffles (respiratory exposure), followed by narcosis. Animals die of respiratory failure from severe nervous system depression. Cloudy swelling of the kidneys was reported in rats following inhalation exposure to 1600 ppm, 18-20 hours/day for 3 days **Subchronic/Chronic Effects:** Repeat doses of toluene cause adverse central nervous system effects and can damage the upper respiratory system, the liver, and the kidney. Adverse effects occur as a result from both oral and the inhalation exposures. A reported lowest-observed-effect level in humans for adverse neurobehavioral effects is 88 ppm. **Humans -** Chronic occupational exposure and incidences of toluene abuse have resulted in hepatomegaly and liver function changes. It has also resulted in nephrotoxicity and, in one case, was a cardiac sensitiser and fatal cardiotoxin. Neural and cerebellar dystrophy were reported in several cases of habitual "glue sniffing." An epidemiological study in France on workers chronically exposed to toluene fumes reported leukopenia and neutropenia. Exposure levels were not given in the secondary reference; however, the average urinary excretion of hippuric acid, a metabolite of toluene, was given as 4 g/L compared to a normal level of 0.6 g/L **Animals -** The major target organs for the subchronic/chronic toxicity of toluene are the nervous system, liver, and kidney. Depressed immune response has been reported in male mice given doses of 105 mg/kg/day for 28 days. Toluene in corn oil administered to F344 male and female rats by gavage 5 days/week for 13 weeks, induced prostration, hypoactivity, ataxia, piloerection, lachrymation, excess salivation, and body tremors at doses 2500 mg/kg. Liver, kidney, and heart weights were also increased at this dose and histopathologic lesions were seen in the liver, kidneys, brain and urinary bladder. The no-observed-adverse effect level (NOAEL) for the study was 312 mg/kg (223 mg/kg/day) and the lowest-observed-adverse effect level (LOAEL) for the study was 625 mg/kg (446 mg/kg/day) . **Developmental/Reproductive Toxicity** Exposures to high levels of toluene can result in adverse effects in the developing human foetus. Several studies have indicated that high levels of toluene can also adversely effect the developing offspring in laboratory animals. **Humans -** Variable growth, microcephaly, CNS dysfunction, attentional deficits, minor craniofacial and limb abnormalities, and developmental delay were seen in three children exposed to toluene in utero as a result of maternal solvent abuse before and during pregnancy **Animals** - Sternebral alterations, extra ribs, and missing tails were reported following treatment of rats with 1500 mg/m3 toluene 24 hours/day during days 9-14 of gestation. Two of the dams died during the exposure. Another group of rats received 1000 mg/m3 8 hours/day during days 1-21 of gestation. No maternal deaths or toxicity occurred, however, minor skeletal retardation was present in the exposed fetuses. CFLP Mice were exposed to 500 or 1500 mg/m3 toluene continuously during days 6-13 of pregnancy. All dams died at the high dose during the first 24 hours of exposure, however none died at 500 mg/m3. Decreased foetal weight was reported, but there were no differences in the incidences of skeletal malformations or anomalies between the treated and control offspring. **Absorption** - Studies in humans and animals have demonstrated that toluene is readily absorbed via the lungs and the gastrointestinal tract. Absorption through the skin is estimated at about 1% of that absorbed by the lungs when exposed to toluene vapor. Dermal absorption is expected to be higher upon exposure to the liquid; however, exposure is limited by the rapid evaporation of toluene . **Distribution** - In studies with mice exposed to radiolabeled toluene by inhalation, high levels of radioactivity were present in body fat, bone marrow, spinal nerves, spinal cord, and brain white matter. Lower levels of radioactivity were present in blood, kidney, and liver. Accumulation of toluene has generally been found in adipose tissue, other tissues with high fat content, and in highly vascularised tissues . **Metabolism** - The metabolites of inhaled or ingested toluene include benzyl alcohol resulting from the hydroxylation of the methyl group. Further oxidation results in the formation of benzaldehyde and benzoic acid. The latter is conjugated with glycine to yield hippuric acid or reacted with glucuronic acid to form benzoyl glucuronide. o-cresol and p-cresol formed by ring hydroxylation are considered minor metabolites **Excretion -** Toluene is primarily (60-70%) excreted through the urine as hippuric acid. The excretion of benzoyl glucuronide accounts for 10-20%, and excretion of unchanged toluene through the lungs also accounts for 10-20%. Excretion of hippuric acid is usually complete within 24 hours after exposure.
TOLUENE-2,4-DIISOCYANATE	The material may produce severe skin irritation after prolonged or repeated exposure, and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) thickening of the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis. Prolonged contact is unlikely, given the severity of response, but repeated exposures may produce severe ulceration. for diisocyanates: In general, there appears to be little or no difference between aromatic and aliphatic diisocyanates as toxicants. In addition, there are insufficient data available to make any major distinctions between polymeric (<1000 MW) and monomeric diisocyanates. Based on repeated dose studies in animals by the inhalation route, both aromatic and aliphatic diisocyanates appear to be of high concern for pulmonary toxicity at low exposure levels. Based upon a very limited data set, it appears that diisocyanate prepolymers exhibit the same respiratory tract effects as the monomers in repeated dose studies. There is also evidence that both aromatic and aliphatic diisocyanates are acutely toxic via the inhalation route. Most members of the diisocyanate category have not been tested for carcinogenic potential. Though the aromatic diisocyanates tested positive and the one aliphatic diisocyanate tested negative in one species, it is premature to make any generalizations about the carcinogenic potential of aromatic versus aliphatic diisocyanates. In the absence of more human data, it would be prudent at this time to assume that both aromatic and aliphatic diisocyanates are respiratory sensitisers. Diisocyanates are moderate to strong dermal sensitisers in animal studies. Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanates. For monomers, effects on the respiratory tract (lungs and nasal cavities) were observed in animal studies at exposure concentrations of less than 0.005 mg/L. The experimental animal data available on prepolymeric diisocyanates show similar adverse effects at levels that range from 0.002 mg/L to 0.026 mg/L. There is also evidence that both aromatic and aliphatic diisocyanates are acutely toxic via the inhalation route **Oncogenicity:** Most members of the diisocyanate category have not been tested for carcinogenic potential. Commercially available Poly-MDI was tested in a 2-year inhalation study in rats. The tested material contained 47% aromatic 4,4'-methylenediphenyl diisocyanate (MDI) and 53% higher molecular weight oligomers. Interim sacrifices at one year showed that males and females in the highest dose group (6 mg/m3) had treatment related histological changes in the nasal cavity, lungs and mediastinal lymph nodes. The incidence and severity of degeneration and basal cell hyperplasia of the olfactory epithelium and Bowman's gland hyperplasia were increased in males at the mid and high doses and in females at the high dose following the two year exposure period. Pulmonary adenomas were found in 6 males and 2

Continued...

	females, and pulmonary adenocarcinoma in one male in the high dose group. However, aliphatic hexamethylene diisocyanate (HDI) was found not to be carcinogenic in a two year repeated dose study in rats by the inhalation route. HDI has not been tested in mice by the inhalation route. Though the oral route is not an expected route of exposure to humans, it should be noted that in two year repeated dose studies by the oral route, aromatic toluene diisocyanate (TDI) and 3,3'-dimethoxy-benzidine-4,4'-diisocyanate (dianisidine diisocyanate, DADI) were found to be carcinogenic in rodents. TDI induced a statistically significant increase in the incidence of liver tumors in rats and mice as well as dose-related hemangiosarcomas of the circulatory system and has been classified by the Agency as a B2 carcinogen. DADI was found to be carcinogenic in rats, but not in mice, with a statistically increase in the incidence of pancreatic tumors observed. **Respiratory and Dermal Sensitization:** Based on the available toxicity data in animals and epidemiologic studies of humans, aromatic diisocyanates such as TDI and MDI are strong respiratory sensitisers. Aliphatic diisocyanates are generally not active in animal models for respiratory sensitization. However, HDI and possibly isophorone diisocyanate (IPDI), are reported to be associated with respiratory sensitization in humans. Symptoms resulting from occupational exposure to HDI include shortness of breath, increased bronchoconstriction reaction to histamine challenges, asthmatic reactions, wheezing and coughing. Two case reports of human exposure to IPDI by inhalation suggest IPDI is a respiratory sensitiser in humans. In view of the information from case reports in humans, it would be prudent at this time to assume that both aromatic and aliphatic diisocyanates are respiratory sensitisers. Studies in both human and mice using TDI, HDI, MDI and dicyclohexylmethane-4,4'-diisocyanate (HMDI) suggest cross-reactivity with the other diisocyanates, irrespective of whether the challenge compound was an aliphatic or aromatic diisocyanate. Diisocyanates are moderate to strong dermal sensitisers in animal studies. There seems to be little or no difference in the level of reactivity between aromatic and aliphatic diisocyanates. **Dermal Irritation:** Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanates. The level of irritation ranged from slightly to severely irritating to the skin. One chemical, hydrogenated MDI (1,1-methylenebis-4-isocyanatocyclohexane), was found to be corrosive to the skin in guinea pigs. Tenth Annual Report on Carcinogens: Substance anticipated to be Carcinogen [*National Toxicology Program: U.S. Dep. of Health & Human Services 2002*]
3-IODO-2-PROPYNYL BUTYL CARBAMATE	for carbamates: Carbamates are effective insecticides by virtue of their ability to inhibit acetylcholinesterase (AChE) (EC 3.1.1.7) in the nervous system. They can also inhibit other esterases. The carbamylation of the enzyme is unstable, and the regeneration of AChE is relatively rapid compared with that from a phosphorylated enzyme. Thus, carbamate pesticides are less dangerous with regard to human exposure than organophosphorus pesticides. The ratio between the dose required to produce death and the dose required to produce minimum symptoms of poisoning is substantially larger for carbamate compounds than for organophosphorus compounds. A dose-effect relationship exists between the dose, the severity of symptoms, and the degree of cholinesterase (ChE) inhibition. Because most carbamates have a low volatility, inhalation studies are mainly carried out using a dust or mist. In these studies, the toxicity is highly dependent on the size of the particles or droplets and, therefore, difficult to evaluate. The acute dermal toxicity of carbamates is generally low to moderate. From controlled human studies, it is clear that poisoning symptoms can be seen a few minutes after exposure, and can last for a few hours. Thereafter, recovery starts and within hours, the symptoms disappear, and the ChE activity in erythrocytes and plasma returns to normal, because the carbamate is rather rapidly metabolised and the metabolites excreted. The appearance of these metabolites in the urine may be used for biological monitoring. Apart from the symptoms indicative of ChE poisoning, other signs and symptoms induced by certain carbamates have been described, such as skin and eye irritation, hyperpigmentation, and influence on the function of testes (slight increase of sperm abnormalities). These signs and symptoms were found in a few studies and should be confirmed before it can be stated that they were induced by carbamates. Epidemiological studies with persons primarily exposed to carbamates are not available. Carbamates produce slight to moderate skin and eye irritation, depending on the vehicle used, duration of contact, and on whether the substance is applied to the abraded or intact skin. From the available data, it cannot be excluded that some of the carbamates will have a slight to moderate sensitization potential. Short- and long-term toxicity studies have been carried out. Some carbamates are very toxic and others are less toxic in long- term studies. From these studies, it is evident that, apart from the anticholinesterase activity, the following changes can be found: an influence on the haemopoietic system, an influence on the functioning of, and, at higher dosages, degeneration of, the liver and kidneys, and degeneration of testes. These abnormalities in the different organ systems depend on the animal strain and on the chemical structure of the carbamate. A clear influence on the nervous system, functional as well as histological, was found, particularly in non-laboratory animals such as pigs. A considerable number of reproduction and teratogenicity studies have been carried out with different carbamates and various animal species. Different types of abnormalities were found, i.e., increase in mortality, disturbance of the endocrine system, and effects on the hypophysis and its gonadotrophic function. These effects were mainly seen at high dose levels. Generally, the fetal effects included an increase in mortality, decreased weight gain in the first weeks after birth, and induction of early embryonic death. All these effects can be summarized as embryotoxic effects. Certain carbamates also induce teratogenic effects, mainly at high dose levels applied by stomach tube. When the same dose level was administered with the diet, no effects were seen. Some carbamates induce mutagenic effects, others are negative. In general, the methyl carbamates are negative in mammalian tests, while compounds such as carbendazim, benomyl, and the 2 thiophanate derivatives showed a positive effect with very high dose levels in certain systems. The benzimidazole moiety may act as a base analogue for DNA and as a spindle poison. They are antimitotic agents and cause mitotic arrest, mitotic delay, and a low incidence of chromosome damage. Sometimes, the results are contradictory or cannot be reproduced, but positive results for point mutation and chromosome aberrations are well documented. These benzimidazole derivatives can be considered as weak mutagenic compounds. Carcinogenicity studies with benzimidazole derivatives showed either positive or equivocal results. Added to the fact that certain mutagenicity studies also give positive results, it cannot be excluded that these compounds may have carcinogenic or promotor properties. Carbamate pesticides may be converted to *N* -nitroso compounds. This was demonstrated in a great number of *in vivo* nitrosation studies in which high levels of the carbamates were administered to animals in combination with high levels of nitrite. These *N* - nitroso compounds have to be considered as mutagenic and carcinogenic. However, the amount of nitroso compounds that can be expected to result from dietary intake of carbamate pesticide residues is negligible in comparison with nitroso-precursors that occur naturally in food and drinking-water. The metabolic fate of carbamates is basically the same in plants, insects, and mammals. Carbamates are usually easily absorbed through the skin, mucous membranes, and respiratory and gastrointestinal tracts, but there are exceptions. Generally, the metabolites are less toxic than the parent compounds. However, in certain cases, the metabolites are just as toxic or even more toxic than the parent carbamate. In most mammals, the metabolites are mainly excreted rather rapidly in the urine. The dog seems to be different in this respect. Accumulation takes place in certain cases, but is of minor importance because of the rapid metabolism. The first step in the metabolism of carbamates is hydrolysis to carbamic acid, which decomposes to carbon dioxide (CO2) and the corresponding amine. The rate of hydrolysis by esterases is faster in mammals than in plants and insects. The organs in which residues have been reported are the liver, kidneys, brain, fat, and muscle. The half-life in the rat is of the order of 3 - 8 h. From the limited data available, it seems that the excretion of carbamates via urine is also rapid in man, and that the metabolic pathways in man are the same as those in the rat for 3-iodo-2-propynyl butyl carbamate (IPBC): **Acute toxicity:** Acceptable acute toxicity studies with IPBC indicate low toxicity except eye irritation. In a primary eye irritation study in rabbi. IPBC technical was severely irritating to the eyes of white rabbits, with corneal opacity and corneal vascularization reported in unwashed eyes by day 21 post-treatment. The technical grade of IPBC was slightly irritating to the skin of white rabbits. In a dermal sensitization study in Guinea pigs IPBC technical, at a concentration of 0.32%, produced no evidence of sensitization in male and female Guinea pigs. **Subchronic toxicity:** In a subchronic oral toxicity study, male and female Sprague-Dawley rats received IPBC technical by gavage for 13 weeks at doses of 0, 20, 50, and 125 mg/kg/day. At the 125 mg/kg/day dose level, body weight gain was decreased by 19% in male rats for weeks 1-13 of the study, and by 12% in female rats over the same period. Absolute liver weight was increased by 20% in male rats at the 125 mg/kg/day dose, and by 31% in female rats at this dose level. Liver to body weight ratio was significantly increased by approximately 31% in both male and female rats at the 125 mg/kg/day dose level, while kidney to body weight ratio in female rats was increased 18% at the 125 mg/kg/day dose level. The systemic NOEL was considered to be 20 mg/kg/day, while the systemic LEL was considered to be 50 mg/kg/day, based on increased liver to body weight ratio.

Continued...

	In a subchronic dermal toxicity study, male and female Sprague-Dawley rats (10/sex/dose) received dermal doses of 50, 200, and 500 mg/kg/day IPBC technical grade (97.5%) to the shaved skin for five days a week, six hours per day. At the 500 mg/kg/day dose, decreased body weight (4-6%) and weight gain (11%) were observed in male rats, but not in female rats. In female rats, significant increases in haemoglobin, haematocrit, and eosinophils were observed at the 500 mg/kg/day dose level. Reticulocytes as a percentage of red cells were decreased in the 50 and 200 mg/kg/day dose groups but not at the 500 mg/kg/day dose level. Females in this study showed inhibition of plasma cholinesterase at 500 mg/k/day test article, which may have been the result of either direct liver toxicity or inhibition of cholinesterase itself. Based upon the results of this study, the systemic NOEL is 200 mg/kg/day, the systemic LEL is 500 mg/kg/day for male and female rats. **Carcinogenicity:** In a 2-year chronic toxicity/carcinogenicity study, technical grade IPBC (98.68% ai) was administered to male and female Sprague Dawley rats (50/sex/group) at dose levels of 0, 20, 40, and 80 mg/kg/day. There were no statistically significant increases in tumor incidences in male rats. The incidence of mammary gland fibroadenoma and combined fibroadenoma/carcinoma in female rats was significantly increased at the 20 mg/kg/day dose level but there was no dose-related trend. **Developmental and reproductive toxicity:** The developmental toxicity of IPBC was assessed in pregnant Sprague-Dawley rats on gestation days six through 15 by oral administration of the test chemical at doses of 0, 20, 50, and 125 mg/kg/day. Maternal toxicity as reduced body weight gain during dosing was observed at the 125 mg/kg/day dose level. Developmental toxicity consisted of an increased incidence of skeletal abnormalities at the 125 mg/kg/day dose level. The maternal toxicity NOEL was determined to be 50 mg/kg/day, and the maternal toxicity LEL was determined to be 125 mg/kg/day, based on reduced body weight gain. The developmental toxicity NOEL was determined to be 50 mg/kg/day, and the developmental toxicity LEL was determined to be 125 mg/kg/day, based on incompletely ossified frontal skull bones and pelvic girdles. A 2-generation reproductive toxicity study was conducted in male and female Sprague- Dawley rats. IPBC technical was administered over two generations at doses of 0, 120, 300, and 750 ppm (0, 6, 15, and 37.5 mg/kg/day). Reduced body weight and food consumption was observed for P1 and F1 males during the premating period at the 37.5 mg/kg/day dose. A decreased mean live birth index was reported for P1 and F1 generations without an effect on viability and development of pups. No adverse effects on reproductive indices or mating performance were observed at any dose level. The parental toxicity NOEL was determined to be 15 mg/kg/day, and the parental toxicity LEL was determined to be 37.5 mg/kg/day, based on decreased body weight and food consumption during premating for P1 and F1 males, and decreased mean live birth index for the P1 and F1 generations. The reproductive toxicity Noel was determined to be 37.5 mg/kg/day, and the reproductive toxicity LEL was determined to be >37.5 mg/kg/day. **Mutagenicity:** In a mutagenicity study, IPBC technical was tested for the ability to cause mutations in *Salmonella typhimurium* strains TA 1535, TA 1537, TA 1538, TA 98, and TA 100. In the five strains used, IPBC was found to be non-mutagenic in the presence or absence of metabolic activation at the concentrations tested, 1-1000 jig/plate . In a micronucleus assay in mice, IPBC at doses of 200, 600, and 2000 mg/kg did not induce any significant increase of the PCE containing micronuclei from the treated mice when compared to that of the vehicle control mice. In two independent unscheduled DNA synthesis (UDS) assays in primary rat hepatocytes, eight doses of IPBC ranging from 3.0 to 13.5 ug/ml did not cause an appreciable increase in mean net nuclear grain counts. Doses >13.5 ug/ml were cytotoxic, supporting the conclusion that IPBC induced cytotoxicity but no genotoxicity in this assay. **Metabolism:** Based on the metabolite identification data, a scheme for metabolism of IPBC was proposed. According to this scheme, IPBC undergoes reductive dehalogenation followed by dealkylation to form the URM-9 and URM-10 metabolites. In addition, de-carboxylation following reductive dehalogenation yields carbon dioxide. Various other metabolites formed from dehalogenation are glucuronidated and constitute minor metabolites of IPBC..
TDI, POLYTETRAHYDROFURAN, PROPOXYLATED & HEXAMETHYLENE DIISOCYANATE POLYMER & 4-METHYLHEXAHYDROPHTHALIC ANHYDRIDE & TOLUENE-2,4-DIISOCYANATE & 3-IODO-2-PROPYNYL BUTYL CARBAMATE	The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.
TDI, POLYTETRAHYDROFURAN, PROPOXYLATED & HEXAMETHYLENE DIISOCYANATE POLYMER & TOLUENE-2,4-DIISOCYANATE	Isocyanate vapours/mists are irritating to the upper respiratory tract and lungs; the response may be severe enough to produce bronchitis with wheezing, gasping and severe distress, even sudden loss of consciousness, and pulmonary oedema. Possible neurological symptoms arising from isocyanate exposure include headache, insomnia, euphoria, ataxia, anxiety neurosis, depression and paranoia. Gastrointestinal disturbances are characterised by nausea and vomiting. Pulmonary sensitisation may produce asthmatic reactions ranging from minor breathing difficulties to severe allergic attacks; this may occur following a single acute exposure or may develop without warning after a period of tolerance. A respiratory response may occur following minor skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities. Isocyanate-containing vapours/ mists may cause inflammation of eyes and nasal passages. Onset of symptoms may be immediate or delayed for several hours after exposure. Sensitised people can react to very low levels of airborne isocyanates. Unprotected or sensitised persons should not be allowed to work in situations allowing exposure to this material.
TDI, POLYTETRAHYDROFURAN, PROPOXYLATED & HEXAMETHYLENE DIISOCYANATE POLYMER & 4-METHYLHEXAHYDROPHTHALIC ANHYDRIDE	No significant acute toxicological data identified in literature search.
XYLENE & ETHYLBENZENE & TOLUENE-2,4-DIISOCYANATE	The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.
XYLENE & HEXAMETHYLENE DIISOCYANATE POLYMER & 4-METHYLHEXAHYDROPHTHALIC ANHYDRIDE & TOLUENE	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.
ETHYLBENZENE & 4-FORMYLMORPHOLINE	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.
ETHYLBENZENE & TOLUENE-2,4-DIISOCYANATE	**WARNING:** This substance has been classified by the IARC as Group 2B: Possibly Carcinogenic to Humans.
HEXAMETHYLENE DIISOCYANATE POLYMER & 4-METHYLHEXAHYDROPHTHALIC ANHYDRIDE & TOLUENE-2,4-DIISOCYANATE	Allergic reactions which develop in the respiratory passages as bronchial asthma or rhinoconjunctivitis, are mostly the result of reactions of the allergen with specific antibodies of the IgE class and belong in their reaction rates to the manifestation of the immediate type. In addition to the allergen-specific potential for causing respiratory sensitisation, the amount of the allergen, the exposure period and the genetically determined disposition of the exposed person are likely to be decisive. Factors which increase the sensitivity of the mucosa may play a role in predisposing a person to allergy. They may be genetically determined or acquired, for example, during infections or exposure to irritant substances. Immunologically the low molecular weight substances become complete allergens in the organism either by binding to peptides or proteins (haptens) or after metabolism (prohaptens). Particular attention is drawn to so-called atopic diathesis which is characterised by an increased susceptibility to allergic rhinitis, allergic bronchial asthma and atopic eczema (neurodermatitis) which is associated with increased IgE synthesis.

Continued...

	Exogenous allergic alveolitis is induced essentially by allergen specific immune-complexes of the IgG type; cell-mediated reactions (T lymphocytes) may be involved. Such allergy is of the delayed type with onset up to four hours following exposure.
4-FORMYLMORPHOLINE & TOLUENE-2,4-DIISOCYANATE	Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production.

Acute Toxicity	✗	**Carcinogenicity**	✓
Skin Irritation/Corrosion	✓	**Reproductivity**	✗
Serious Eye Damage/Irritation	✓	**STOT - Single Exposure**	✓
Respiratory or Skin sensitisation	✓	**STOT - Repeated Exposure**	✗
Mutagenicity	✗	**Aspiration Hazard**	✗

Legend: ✗ *– Data either not available or does not fill the criteria for classification*
✓ *– Data available to make classification*

SECTION 12 Ecological information

Toxicity

ALSAN QUADRO

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

TDI, polytetrahydrofuran, propoxylated

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

xylene

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	4.6mg/l	2
LC50	96h	Fish	2.6mg/l	2
EC50	48h	Crustacea	1.8mg/l	2
NOEC(ECx)	73h	Algae or other aquatic plants	0.44mg/l	2

ethylbenzene

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	4.6mg/l	1
LC50	96h	Fish	3.381-4.075mg/L	4
EC50	48h	Crustacea	1.37-4.4mg/l	4
NOEC(ECx)	720h	Fish	0.381mg/L	4
EC50	96h	Algae or other aquatic plants	3.6mg/l	2

hydrocarbons, C9-unsaturated, polymers with phenol

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

hexamethylene diisocyanate polymer

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	>1000mg/l	2
LC50	96h	Fish	8.9mg/l	2
NOEC(ECx)	72h	Algae or other aquatic plants	50mg/l	2

4-formylmorpholine

Endpoint	Test Duration (hr)	Species	Value	Source
NOEC(ECx)	Not Available	Crustacea	>1mg/l	2
EC50	72h	Algae or other aquatic plants	17440mg/l	2
LC50	96h	Fish	>500mg/l	2
EC50	48h	Crustacea	>500mg/l	2

4-methylhexahydrophthalic anhydride

Endpoint	Test Duration (hr)	Species	Value	Source
BCF	1008h	Fish	<0.2	7
EC50	72h	Algae or other aquatic plants	81.3mg/l	2
LC50	96h	Fish	>100mg/l	2
EC50	48h	Crustacea	>100mg/l	2

Continued...

	EC50(ECx)	504h	Crustacea	9.2mg/l	2

toluene					
	Endpoint	**Test Duration (hr)**	**Species**	**Value**	**Source**
	LC50	96h	Fish	5-35mg/l	4
	EC50	48h	Crustacea	3.78mg/L	5
	NOEC(ECx)	168h	Crustacea	0.74mg/L	5
	EC50	96h	Algae or other aquatic plants	>376.71mg/L	4

toluene-2,4-diisocyanate					
	Endpoint	**Test Duration (hr)**	**Species**	**Value**	**Source**
	LC50	96h	Fish	108.8-240.4mg/l	4
	EC50	48h	Crustacea	12.5mg/l	2
	EC50	96h	Algae or other aquatic plants	3230mg/l	2
	BCF	1440h	Fish	25-380	7
	NOEC(ECx)	504h	Crustacea	0.5mg/l	2

3-iodo-2-propynyl butyl carbamate					
	Endpoint	**Test Duration (hr)**	**Species**	**Value**	**Source**
	NOEC(ECx)	840h	Fish	0.013mg/L	4
	LC50	96h	Fish	0.077-0.124mg/L	4
	EC50	48h	Crustacea	0.04mg/L	5

Legend:	*Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data*

Toxic to aquatic organisms.
Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
Do NOT allow product to come in contact with surface waters or to intertidal areas below the mean high water mark. Do not contaminate water when cleaning equipment or disposing of equipment wash-waters.
Wastes resulting from use of the product must be disposed of on site or at approved waste sites.
DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
xylene	HIGH (Half-life = 360 days)	LOW (Half-life = 1.83 days)
ethylbenzene	HIGH (Half-life = 228 days)	LOW (Half-life = 3.57 days)
hexamethylene diisocyanate polymer	HIGH	HIGH
4-formylmorpholine	LOW	LOW
4-methylhexahydrophthalic anhydride	HIGH	HIGH
toluene	LOW (Half-life = 28 days)	LOW (Half-life = 4.33 days)
toluene-2,4-diisocyanate	HIGH	HIGH
3-iodo-2-propynyl butyl carbamate	HIGH	HIGH

Bioaccumulative potential

Ingredient	Bioaccumulation
xylene	MEDIUM (BCF = 740)
ethylbenzene	LOW (BCF = 79.43)
hexamethylene diisocyanate polymer	LOW (LogKOW = 7.5795)
4-formylmorpholine	LOW (LogKOW = -1.3205)
4-methylhexahydrophthalic anhydride	LOW (BCF = 2.4)
toluene	LOW (BCF = 90)
toluene-2,4-diisocyanate	LOW (BCF = 5)
3-iodo-2-propynyl butyl carbamate	LOW (LogKOW = 2.4542)

Mobility in soil

Ingredient	Mobility
ethylbenzene	LOW (KOC = 517.8)
hexamethylene diisocyanate polymer	LOW (KOC = 18560000)
4-formylmorpholine	HIGH (KOC = 1.003)
4-methylhexahydrophthalic anhydride	LOW (KOC = 17.56)

Continued...

Ingredient	Mobility
toluene	LOW (KOC = 268)
toluene-2,4-diisocyanate	LOW (KOC = 9114)
3-iodo-2-propynyl butyl carbamate	LOW (KOC = 365.3)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal	▸ Containers may still present a chemical hazard/ danger when empty. ▸ Return to supplier for reuse/ recycling if possible. Otherwise: ▸ If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill. ▸ Where possible retain label warnings and SDS and observe all notices pertaining to the product. Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked. A Hierarchy of Controls seems to be common - the user should investigate: ▸ Reduction ▸ Reuse ▸ Recycling ▸ Disposal (if all else fails) This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate. ▸ **DO NOT** allow wash water from cleaning or process equipment to enter drains. ▸ It may be necessary to collect all wash water for treatment before disposal. ▸ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. ▸ Where in doubt contact the responsible authority. ▸ Recycle wherever possible. ▸ Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified. ▸ Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or Incineration in a licensed apparatus (after admixture with suitable combustible material). ▸ Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

SECTION 14 Transport information

Labels Required

	
Marine Pollutant	NO
HAZCHEM	•3Y

Land transport (ADG)

UN number	1263
UN proper shipping name	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base) or PAINT RELATED MATERIAL (including paint thinning or reducing compound)
Transport hazard class(es)	Class: 3 Subrisk: Not Applicable
Packing group	III
Environmental hazard	Not Applicable
Special precautions for user	Special provisions: 163 223 367 Limited quantity: 5 L

Air transport (ICAO-IATA / DGR)

UN number	1263
UN proper shipping name	Paint (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base)
Transport hazard class(es)	ICAO/IATA Class: 3 ICAO / IATA Subrisk: Not Applicable ERG Code: 3L
Packing group	III
Environmental hazard	Not Applicable

Continued...

Special precautions for user	Special provisions	A3 A72 A192
	Cargo Only Packing Instructions	366
	Cargo Only Maximum Qty / Pack	220 L
	Passenger and Cargo Packing Instructions	355
	Passenger and Cargo Maximum Qty / Pack	60 L
	Passenger and Cargo Limited Quantity Packing Instructions	Y344
	Passenger and Cargo Limited Maximum Qty / Pack	10 L

Sea transport (IMDG-Code / GGVSee)

UN number	1263
UN proper shipping name	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base) or PAINT RELATED MATERIAL (including paint thinning or reducing compound)
Transport hazard class(es)	IMDG Class: 3 IMDG Subrisk: Not Applicable
Packing group	III
Environmental hazard	Not Applicable
Special precautions for user	EMS Number: F-E , S-E Special provisions: 163 223 367 955 Limited Quantities: 5 L

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
TDI, polytetrahydrofuran, propoxylated	Not Available
xylene	Not Available
ethylbenzene	Not Available
hydrocarbons, C9-unsaturated, polymers with phenol	Not Available
hexamethylene diisocyanate polymer	Not Available
4-formylmorpholine	Not Available
4-methylhexahydrophthalic anhydride	Not Available
toluene	Not Available
toluene-2,4-diisocyanate	Not Available
3-iodo-2-propynyl butyl carbamate	Not Available

Transport in bulk in accordance with the ICG Code

Product name	Ship Type
TDI, polytetrahydrofuran, propoxylated	Not Available
xylene	Not Available
ethylbenzene	Not Available
hydrocarbons, C9-unsaturated, polymers with phenol	Not Available
hexamethylene diisocyanate polymer	Not Available
4-formylmorpholine	Not Available
4-methylhexahydrophthalic anhydride	Not Available
toluene	Not Available
toluene-2,4-diisocyanate	Not Available
3-iodo-2-propynyl butyl carbamate	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

TDI, polytetrahydrofuran, propoxylated is found on the following regulatory lists

Continued...

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australian Inventory of Industrial Chemicals (AIIC)

xylene is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

ethylbenzene is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans

hydrocarbons, C9-unsaturated, polymers with phenol is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

hexamethylene diisocyanate polymer is found on the following regulatory lists

Australia Model Work Health and Safety Regulations - Hazardous chemicals (other than lead) requiring health monitoring
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)

4-formylmorpholine is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

4-methylhexahydrophthalic anhydride is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List

toluene is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

toluene-2,4-diisocyanate is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Model Work Health and Safety Regulations - Hazardous chemicals (other than lead) requiring health monitoring
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans

3-iodo-2-propynyl butyl carbamate is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	Yes
Canada - DSL	Yes
Canada - NDSL	No (TDI, polytetrahydrofuran, propoxylated; xylene; ethylbenzene; 4-formylmorpholine; 4-methylhexahydrophthalic anhydride; toluene; toluene-2,4-diisocyanate; 3-iodo-2-propynyl butyl carbamate)
China - IECSC	No (TDI, polytetrahydrofuran, propoxylated)
Europe - EINEC / ELINCS / NLP	No (TDI, polytetrahydrofuran, propoxylated)
Japan - ENCS	No (TDI, polytetrahydrofuran, propoxylated; hydrocarbons, C9-unsaturated, polymers with phenol; hexamethylene diisocyanate polymer)
Korea - KECI	No (TDI, polytetrahydrofuran, propoxylated)
New Zealand - NZIoC	Yes
Philippines - PICCS	Yes
USA - TSCA	Yes
Taiwan - TCSI	Yes
Mexico - INSQ	No (TDI, polytetrahydrofuran, propoxylated; hydrocarbons, C9-unsaturated, polymers with phenol; hexamethylene diisocyanate polymer; 4-formylmorpholine; 4-methylhexahydrophthalic anhydride)
Vietnam - NCI	Yes
Russia - FBEPH	No (TDI, polytetrahydrofuran, propoxylated; hydrocarbons, C9-unsaturated, polymers with phenol)
Legend:	*Yes = All CAS declared ingredients are on the inventory* *No = One or more of the CAS listed ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)*

Continued...

SECTION 16 Other information

Revision Date	13/07/2021
Initial Date	13/07/2021

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average
PC—STEL: Permissible Concentration-Short Term Exposure Limit
IARC: International Agency for Research on Cancer
ACGIH: American Conference of Governmental Industrial Hygienists
STEL: Short Term Exposure Limit
TEEL: Temporary Emergency Exposure Limit。
IDLH: Immediately Dangerous to Life or Health Concentrations
ES: Exposure Standard
OSF: Odour Safety Factor
NOAEL :No Observed Adverse Effect Level
LOAEL: Lowest Observed Adverse Effect Level
TLV: Threshold Limit Value
LOD: Limit Of Detection
OTV: Odour Threshold Value
BCF: BioConcentration Factors
BEI: Biological Exposure Index
AIIC: Australian Inventory of Industrial Chemicals
DSL: Domestic Substances List
NDSL: Non-Domestic Substances List
IECSC: Inventory of Existing Chemical Substance in China
EINECS: European INventory of Existing Commercial chemical Substances
ELINCS: European List of Notified Chemical Substances
NLP: No-Longer Polymers
ENCS: Existing and New Chemical Substances Inventory
KECI: Korea Existing Chemicals Inventory
NZIoC: New Zealand Inventory of Chemicals
PICCS: Philippine Inventory of Chemicals and Chemical Substances
TSCA: Toxic Substances Control Act
TCSI: Taiwan Chemical Substance Inventory
INSQ: Inventario Nacional de Sustancias Químicas
NCI: National Chemical Inventory
FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances